<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/19/integra-lifesciences-holdings-corp-nasdaqiart-receives-61-82-consensus-target-price-from-brokerages.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-19T22:04:41+00:00"/>
    <meta property="og:title" content="Integra Lifesciences Holdings Corp (NASDAQ:IART) Receives $61.82 Consensus Target Price from Brokerages"/>
    <meta property="og:description" content="Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) have received a consensus rating of “Hold” from the fourteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. The […]"/>
  </head>
  <body>
    <article>
      <h1>Integra Lifesciences Holdings Corp (NASDAQ:IART) Receives $61.82 Consensus Target Price from Brokerages</h1>
      <address><time datetime="2019-11-19T22:04:41+00:00">19 Nov 2019, 22:04</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/integra-lifesciences-holdings-corp-logo.png"/>
      </figure>
      <p>Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) have received a consensus rating of “Hold” from the fourteen brokerages that are presently covering the firm, <a href="https://www.marketbeat.com/">Marketbeat Ratings</a> reports. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $61.82.</p>
      <p>A number of research analysts have commented on the company. BTIG Research set a $70.00 price objective on Integra Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, July 24th. BidaskClub cut Integra Lifesciences from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Wells Fargo &amp; Co set a $62.00 price target on Integra Lifesciences and gave the stock a “hold” rating in a research note on Friday, October 25th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=IART">ValuEngine</a> cut Integra Lifesciences from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 14th. Finally, TheStreet cut Integra Lifesciences from an “a-” rating to a “c+” rating in a research note on Thursday, October 24th.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/IART/price-target/">IART</a> traded up $0.90 during midday trading on Thursday, reaching $58.92. 289,300 shares of the company were exchanged, compared to its average volume of 442,455. The stock has a 50-day moving average price of $59.20 and a 200-day moving average price of $56.82. The company has a market cap of $5.02 billion, a price-to-earnings ratio of 24.35, a P/E/G ratio of 1.72 and a beta of 1.09. Integra Lifesciences has a 1-year low of $42.14 and a 1-year high of $65.09. The company has a current ratio of 2.92, a quick ratio of 1.92 and a debt-to-equity ratio of 1.07.</p>
      <p>Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings data on Thursday, October 24th. The life sciences company reported $0.68 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.03. The company had revenue of $379.10 million for the quarter, compared to analysts’ expectations of $376.85 million. Integra Lifesciences had a return on equity of 16.83% and a net margin of 3.99%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.59 earnings per share. Equities research analysts anticipate that Integra Lifesciences will post 2.74 earnings per share for the current year.</p>
      <p>In related news, VP John Mooradian sold 7,000 shares of the business’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $61.42, for a total value of $429,940.00. Following the completion of the sale, the vice president now directly owns 15,410 shares of the company’s stock, valued at $946,482.20. The sale was disclosed in a filing with the SEC, which can be accessed through <a href="https://www.sec.gov/Archives/edgar/data/917520/000120919119047400/xslF345X03/doc4.xml">this link</a>. Also, major shareholder Richard E. Caruso sold 520,000 shares of the business’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $60.97, for a total value of $31,704,400.00. Following the completion of the sale, the insider now directly owns 134,134 shares of the company’s stock, valued at $8,178,149.98. The disclosure for this sale can be found <a href="https://www.sec.gov/Archives/edgar/data/917520/000120919119050354/xslF345X03/doc4.xml">here</a>. In the last quarter, insiders sold 866,249 shares of company stock worth $52,791,780. Insiders own 4.50% of the company’s stock.</p>
      <p>A number of institutional investors have recently made changes to their positions in IART. Steward Partners Investment Advisory LLC bought a new stake in Integra Lifesciences in the second quarter valued at about $26,000. Quadrant Capital Group LLC increased its holdings in Integra Lifesciences by 239.0% in the third quarter. Quadrant Capital Group LLC now owns 556 shares of the life sciences company’s stock valued at $31,000 after buying an additional 392 shares during the last quarter. World Asset Management Inc bought a new stake in Integra Lifesciences in the third quarter valued at about $200,000. Zions Bancorporation N.A. increased its holdings in Integra Lifesciences by 5.9% in the second quarter. Zions Bancorporation N.A. now owns 4,359 shares of the life sciences company’s stock valued at $243,000 after buying an additional 242 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Integra Lifesciences by 8.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,581 shares of the life sciences company’s stock valued at $275,000 after buying an additional 360 shares during the last quarter. 80.61% of the stock is owned by hedge funds and other institutional investors.</p>
      <p>
        <b>Integra Lifesciences Company Profile</b>
      </p>
      <p>Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.</p>
      <p>Recommended Story: <a href="https://www.marketbeat.com/dividends/aristocrats/">What is the Dividend Aristocrat Index?</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=IART"/>
      </figure>
    </article>
  </body>
</html>